Overview
AGIO market data
Price History
AGIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.12 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.65 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -418.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.24 – $46.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2B · P/B 1.33 · P/S 20.77.
Company News
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34Benzinga · Aug 7, 2026, 3:36 PM
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52Benzinga · Jul 31, 2026, 7:36 PM
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39Benzinga · Jul 31, 2026, 12:54 PM
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55Benzinga · Jul 30, 2026, 7:33 PM
Agios Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.Benzinga · Jul 30, 2026, 4:59 PM
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M EstimateBenzinga · Jul 30, 2026, 10:31 AM
Agios Reports Neutral Sickle Cell Data, Decides To Stop DevelopmentBenzinga · Jul 21, 2026, 3:44 PM
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52Benzinga · Jul 21, 2026, 3:31 PM
Agios Pharmaceutical shares are trading lower after the company announced topline results from its Phase 2 trial of tebapivat. Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease.Benzinga · Jul 21, 2026, 1:17 PM
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 21, 2026, 12:01 PM